Hubbry Logo
search
logo

Trafermin

logo
Community Hub0 Subscribers
from Wikipedia
Trafermin
Clinical data
Trade namesFiblast
Other namesCAB-2001; Recombinant human basic fibroblast growth factor; rhbFGF; 2-155-Basic fibroblast growth factor (human clone lambdaKB7/lambdaHFL1 precursor reduced)
Routes of
administration
Topical (spray)[1]
ATC code
Identifiers
CAS Number
PubChem SID
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC764H1201N217O219S6
Molar mass17122.67 g·mol−1

Trafermin (brand name Fiblast), also known as recombinant human basic fibroblast growth factor (rhbFGF), is a recombinant form of human basic fibroblast growth factor (bFGF) which is marketed in Japan as a topical spray for the treatment of skin ulcers.[2][3][1] It is also currently in preregistration for the treatment of periodontitis.[2][4] As a recombinant form of bFGF, trafermin is a potent agonist of the FGFR1, FGFR2, FGFR3, and FGFR4.[5][6] The drug has been marketed in Japan since June 2001.[citation needed]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
User Avatar
No comments yet.